Summary
5.57 0.10(1.83%)10/04/2024
Mind Medicine Inc (MNMD)
Mind Medicine Inc (MNMD)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.02 | -4.95 | -9.29 | -21.29 | -48.47 | 83.06 | 0.00 | -42.81 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 5.57 | |
| Open | 5.50 | |
| High | 5.63 | |
| Low | 5.42 | |
| Volume | 323,416 | |
| Change | 0.11 | |
| Change % | 2.02 | |
| Avg Volume (20 Days) | 580,007 | |
| Volume/Avg Volume (20 Days) Ratio | 0.56 | |
| 52 Week Range | 2.41 - 12.22 | |
| Price vs 52 Week High | -54.46% | |
| Price vs 52 Week Low | 130.91% | |
| Range | 1.18 | |
| Gap Up/Down | -0.05 | |
Fundamentals | ||
| Market Capitalization (Mln) | 479 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 8.00 | |
| Book Value | 0.3940 | |
| Earnings Per Share | -0.1840 | |
| EPS Estimate Current Quarter | -0.0300 | |
| EPS Estimate Next Quarter | -0.0400 | |
| EPS Estimate Current Year | -0.2900 | |
| EPS Estimate Next Year | -0.2900 | |
| Diluted EPS (TTM) | -0.1840 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.5495 | |
| Return on equity (TTM) | -0.9500 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 420,740,992 | |
| Shares Float | 364,340,069 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 15.76 | |
| Institutions (%) | 10.89 | |
08/15 12:30 EST - seekingalpha.com
Psychedelic Stocks: Focus On Their Cash
Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks.
Psychedelic Stocks: Focus On Their Cash
Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks.
08/13 11:21 EST - seekingalpha.com
Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 PM ET Company Participants Robert Barrow - CEO Daniel Karlin - CMO Reid Robison - Senior Principal Investigator, Cedar Clinical Research Conference Call Participants Elaine Kim - Cantor Fitzgerald Brian Abrahams - RBC Capital Markets Rudy Li - Leerink Partners LLC Daniel Hultberg - Oppenheimer Christopher Chen - Robert W. Baird Sumant Kulkarni - Canaccord Genuity Operator Good morning, and welcome to the Mind Medicine Second Quarter 2024 Financial Results and Corporate Update Conference Call.
Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 PM ET Company Participants Robert Barrow - CEO Daniel Karlin - CMO Reid Robison - Senior Principal Investigator, Cedar Clinical Research Conference Call Participants Elaine Kim - Cantor Fitzgerald Brian Abrahams - RBC Capital Markets Rudy Li - Leerink Partners LLC Daniel Hultberg - Oppenheimer Christopher Chen - Robert W. Baird Sumant Kulkarni - Canaccord Genuity Operator Good morning, and welcome to the Mind Medicine Second Quarter 2024 Financial Results and Corporate Update Conference Call.
08/13 07:44 EST - marketwatch.com
MindMed readying Phase III trials for LSD therapy to treat anxiety
MindMed Inc. MNMD, -0.87% said Tuesday it's on track to launch Phase 3 clinical trials with up to 440 people starting later this year for its treatment of generalized anxiety disorder (GAD) through use of lysergide D-tartrate (LSD) in a clinical setting. MindMed is working on FDA approval for an anxiety therapy using LSD.
MindMed readying Phase III trials for LSD therapy to treat anxiety
MindMed Inc. MNMD, -0.87% said Tuesday it's on track to launch Phase 3 clinical trials with up to 440 people starting later this year for its treatment of generalized anxiety disorder (GAD) through use of lysergide D-tartrate (LSD) in a clinical setting. MindMed is working on FDA approval for an anxiety therapy using LSD.
08/13 07:01 EST - businesswire.com
Pacific Defense Announces US Army CMFF Program Team
EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense, a leading provider of Modular Open Systems Approach (MOSA) products and mission solutions, announced their team to compete for the U.S. Army's CMOSS Mounted Form Factor (CMFF) program. Led by Pacific Defense, the CMFF team includes state-of-the-art industry technology leaders Thales Defense & Security Inc., BAE, Regal Technology Partners, Palantir and STC, an Arcfield Company. “Our company is purpose-built to drive the open-systems chang.
Pacific Defense Announces US Army CMFF Program Team
EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense, a leading provider of Modular Open Systems Approach (MOSA) products and mission solutions, announced their team to compete for the U.S. Army's CMOSS Mounted Form Factor (CMFF) program. Led by Pacific Defense, the CMFF team includes state-of-the-art industry technology leaders Thales Defense & Security Inc., BAE, Regal Technology Partners, Palantir and STC, an Arcfield Company. “Our company is purpose-built to drive the open-systems chang.
08/12 12:47 EST - barrons.com
FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates
The Food and Drug Administration rejected Lykos' application to treat PTSD with MDMA therapy. Atai, Compass Pathways, and MindMed are sliding in the wake of the decision.
FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates
The Food and Drug Administration rejected Lykos' application to treat PTSD with MDMA therapy. Atai, Compass Pathways, and MindMed are sliding in the wake of the decision.
08/12 12:12 EST - marketwatch.com
Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder.
Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder.
08/09 06:00 EST - businesswire.com
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. All of the common shares and pre-funded warrants are being offered by MindMed. Min.
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. All of the common shares and pre-funded warrants are being offered by MindMed. Min.
08/07 14:29 EST - seekingalpha.com
MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy
The FDA's decision on MDMA therapy for PTSD is imminent, impacting MindMed investors and the psychedelic medicine industry. An FDA advisory committee voted against approving MDMA therapy, causing market volatility and uncertainty for psychedelic stocks. Major psychedelic stocks like MindMed have the fundamentals and growing FDA support to withstand a negative FDA decision on MDMA therapy.
MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy
The FDA's decision on MDMA therapy for PTSD is imminent, impacting MindMed investors and the psychedelic medicine industry. An FDA advisory committee voted against approving MDMA therapy, causing market volatility and uncertainty for psychedelic stocks. Major psychedelic stocks like MindMed have the fundamentals and growing FDA support to withstand a negative FDA decision on MDMA therapy.
07/06 07:21 EST - investorplace.com
3 Psychedelic Stocks to Ride to the Moon and Beyond
The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.
3 Psychedelic Stocks to Ride to the Moon and Beyond
The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.
07/04 14:13 EST - investorplace.com
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare environment. As a result, biotech breakthrough stocks fell out of favor with investors and were among the worst performers in the stock market.
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare environment. As a result, biotech breakthrough stocks fell out of favor with investors and were among the worst performers in the stock market.
06/21 07:00 EST - businesswire.com
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held on June 27, 2024. A webcast of the fireside chat will be accessible on MindMed's Investor Relations website starting on June 27,.
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held on June 27, 2024. A webcast of the fireside chat will be accessible on MindMed's Investor Relations website starting on June 27,.
06/20 07:00 EST - businesswire.com
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD. “Following a constructive En.
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD. “Following a constructive En.
06/18 12:31 EST - investorplace.com
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuations and high risk, they offer the potential for impressive gains, especially in a bull market.
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuations and high risk, they offer the potential for impressive gains, especially in a bull market.
06/14 10:40 EST - zacks.com
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
05/29 10:46 EST - zacks.com
Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
05/28 07:00 EST - businesswire.com
MindMed to Participate in June Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will participate in the following conferences: BIO International Convention 2024 Panel Name: Challenging Biotech's One-Track Mind When it Comes to Neuropsychiatric Drug Innovation Date and Time: Tuesday, June 4, 2024 at 4:15.
MindMed to Participate in June Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will participate in the following conferences: BIO International Convention 2024 Panel Name: Challenging Biotech's One-Track Mind When it Comes to Neuropsychiatric Drug Innovation Date and Time: Tuesday, June 4, 2024 at 4:15.
05/23 15:41 EST - investorplace.com
The Time Traveler's Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034
Imagine you could go back in time to find last decade's long-term stocks to buy. Nvidia (NASDAQ: NVDA ) returned nearly 20,000% growth since 2014.
The Time Traveler's Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034
Imagine you could go back in time to find last decade's long-term stocks to buy. Nvidia (NASDAQ: NVDA ) returned nearly 20,000% growth since 2014.
05/23 12:15 EST - seekingalpha.com
Psychedelics Closer To Commercialization; Compass Far And Away The Leader
Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through private placements.
Psychedelics Closer To Commercialization; Compass Far And Away The Leader
Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through private placements.
05/10 11:00 EST - investorplace.com
Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May
The stock market continues to question whether a large cap dominance — especially that from The Magnificent Seven — is indeed the best way to invest. While investing in large cap firms is undoubtedly a good strategy, there are plenty of top Russell 2000 stocks to buy.
Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May
The stock market continues to question whether a large cap dominance — especially that from The Magnificent Seven — is indeed the best way to invest. While investing in large cap firms is undoubtedly a good strategy, there are plenty of top Russell 2000 stocks to buy.
05/09 06:49 EST - investorplace.com
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and tighter regulatory conditions squeezing already-thin margins. However, 2024 may herald a resurgence for biotech stocks, spurred by an FDA approval spree throughout 2023.
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and tighter regulatory conditions squeezing already-thin margins. However, 2024 may herald a resurgence for biotech stocks, spurred by an FDA approval spree throughout 2023.